Evidence map›Paper›PMID 23185273›Full record

ArticlePloS one2012

Identification of biological markers of liver X receptor (LXR) activation at the cell surface of human monocytes.

Cédric Rébé, Rodolphe Filomenko, Magalie Raveneau, Angélique Chevriaux, Minako Ishibashi, Laurent Lagrost, Jean Louis Junien, Philippe Gambert, David Masson

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Cédric RébéCentre de Recherche Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 866, Université de Bourgogne, Dijon, France.
Rodolphe Filomenko
Magalie Raveneau
Angélique Chevriaux
Minako Ishibashi
Laurent Lagrost
Jean Louis Junien
Philippe Gambert
David Masson
Université de Bourgogne · FRCentre Georges François Leclerc · FRCentre Hospitalier Universitaire Dijon Bourgogne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLiver X receptor (LXR) α and LXR β (NR1H3 and NR1H2) are oxysterol-activated nuclear receptors involved in the control of major metabolic pathways such as cholesterol homeostasis, lipogenesis, inflammation and innate immunity. Synthetic LXR agonists are currently under development and could find applications in various fields such as cardiovascular diseases, cancer, diabetes and neurodegenerative diseases. The clinical development of LXR agonists requires the identification of biological markers for pharmacodynamic studies. In this context, monocytes represent an attractive target to monitor LXR activation. They are easily accessible cells present in peripheral blood; they express LXR α and β and respond to LXR agonist stimulation in vitro. The aim of our study was to identify cell surface markers of LXR agonists on monocytes. For this, we focused on clusters of differentiation (CD) markers because they are well characterized and accessible cell surface molecules allowing easy immuno-phenotyping. METHODOLOGY/PRINCIPAL

findingsBy using microarray analysis of monocytes treated or not with an LXR agonist in vitro, we selected three CD, i.e. CD82, CD226, CD244 for further analysis by real time PCR and flow cytometry. The three CD were up-regulated by LXR agonist treatment in vitro in a time- and dose- dependent manner and this induction was LXR specific as assessed by a SiRNA or LXR antagonist strategy. By using flow cytometry, we could demonstrate that the expression of these molecules at the cell surface of monocytes was significantly increased after LXR agonist treatment. CONCLUSIONS/SIGNIFICANCE: We have identified three new cell surface markers that could be useful to monitor LXR activation. Future studies will be required to confirm the biological and diagnostic significance of the markers.

Indexed as

Antigens, CDBenzenesulfonamidesBiomarkersCell MembraneCholesterolFluorocarbonsFoam CellsGene Expression RegulationGene Knockdown TechniquesHumansHydrocarbons, FluorinatedLiver X ReceptorsMacrophagesMonocytesOrphan Nuclear ReceptorsRNA, MessengerAntigens, CDBenzenesulfonamidesBiomarkersCholesterolFluorocarbonsHydrocarbons, FluorinatedLiver X ReceptorsNR1H2 protein, humanNR1H3 protein, humanOrphan Nuclear ReceptorsRNA, MessengerSulfonamidesT0901317

Identifiers

PMID23185273
PMCPMC3504056
OpenAlexW1980622884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.